Forbearance Deal Buys Time, but Going-Concern Warning Looms
KPTI is trading near its 52-week low of $1.595 (2.8% above the low).
Summary
Karyopharm missed a $15.8M debt payment, entered a forbearance agreement with creditors, and warned it may not survive past October 15 without new funding. The company will issue $20M of convertible preferred stock as a forbearance fee.
Key Events · Legal and Risk Events · KPTI
-
Forbearance Agreement Signed
Karyopharm entered a forbearance agreement with all lenders, noteholders, and royalty investors after missing a $15.8M principal installment due September 10, 2026. The forbearance period runs until October 15, 2026.
-
Going Concern Warning
The company states it will be unable to continue as a going concern absent additional funding or a strategic transaction beyond October 15, 2026, and may consider bankruptcy, asset liquidation, or ceasing operations.
-
$20M Forbearance Fee in Preferred Stock
Karyopharm will issue 20,000 shares of 0% convertible perpetual preferred stock at $1,000 per share ($20M aggregate) as forbearance consideration. The preferred converts at $1.62 per share, subject to a 19.99% Nasdaq ownership cap until shareholder approval is obtained by March 15, 2027.
-
Debt Defaults and Cross-Defaults
The missed payment constitutes an event of default under the Credit Agreement, with cross-defaults under the Indentures and Royalty Agreement. The company also did not pay cash interest on its Notes on June 30, 2026, and may not satisfy a $25M minimum liquidity covenant after October 10, 2026.
Analysis · KPTI · Life Sciences
After missing a $15.8 million principal payment, Karyopharm has entered a forbearance agreement with all of its lenders. The company now states it will be unable to continue as a going concern absent additional funding or a strategic transaction by October 15, 2026. As part of the arrangement, it is paying a $20 million fee in the form of convertible preferred stock that converts at $1.62 per share — a deeply dilutive structure for existing holders. This filing confirms the worst-case scenario flagged in the August 13 filings, where the company disclosed cash only into September.
How filings like this one have moved
In the 30 days to Sep 11, 2026, 42.5% of the 522 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.49%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, KPTI was trading at $1.64 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $36.7M. The 52-week trading range was $1.60 to $10.99. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.